Vanda Pharmaceuticals agrees with the FDA on resubmission of the application for Hetlioz for the treatment of patients with Smith-Magenis syndrome.
Vanda Pharmaceuticals Inc. announced that following the completion of a Type A Meeting with the FDA on 8 May 2020, it has reached agreement with the FDA to… read more.